Press release
Diabetes Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, and Pipeline Analysis | vTv Therapeutics, Tonghua Dongbao Pharmaceutical, Eli Lilly and Company, Celon Phar
Diabetes Pipeline Analysis
Diabetes Pipeline constitutes 200+ key companies continuously working towards developing 200+ Diabetes treatment therapies, analyzes DelveInsight.
Diabetes Overview:
Diabetes is a long-term metabolic disorder characterized by high blood sugar levels resulting from the body's inability to produce enough insulin or use it effectively. Insulin is a key hormone that regulates glucose levels. The two primary forms are Type 1 diabetes, an autoimmune condition where the immune system destroys insulin-producing cells in the pancreas, and Type 2 diabetes, which is more prevalent and often associated with insulin resistance and lifestyle factors such as obesity and poor dietary habits. Additional types include gestational diabetes, which develops during pregnancy, and less common forms like Maturity-Onset Diabetes of the Young (MODY) and Latent Autoimmune Diabetes in Adults (LADA).
Symptoms vary by type and severity but typically include excessive thirst, frequent urination, increased hunger, unintended weight loss, fatigue, and blurred vision due to unstable glucose levels. Type 2 diabetes may also involve slow-healing wounds, recurrent infections, and numbness or tingling in the extremities-signs of possible nerve damage.
Request for a detailed insights report on Diabetes pipeline insights [https://www.delveinsight.com/report-store/diabetes-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
"Diabetes Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Diabetes Therapeutics Market.
Key Takeaways from the Diabetes Pipeline Report
*
DelveInsight's Diabetes pipeline report depicts a robust space with 180+ active players working to develop 200+ pipeline therapies for Diabetes treatment.
*
In November 2025, GIOSTAR announced that it received FDA clearance for its Investigational New Drug (IND) application to begin a Phase 2 clinical trial for the development of a targeted stem cell therapy for Type II Diabetes.
*
In January 2025, Glenmark Pharmaceuticals Ltd., a global research-driven pharmaceutical company, introduced a biosimilar of the widely used anti-diabetic drug Liraglutide in India for the first time.
*
Key Diabetes companies such as vTv Therapeutics, Tonghua Dongbao Pharmaceutical, Eli Lilly and Company, Celon Pharma, Sciwind Biosciences, AstraZeneca, Suzhou Alphamab Co., Ltd., Neurodon, Abarceo Pharma, Chong Kun Dang Pharmaceutical, and others are evaluating new drugs for Diabetes to improve the treatment landscape.
*
Promising Diabetes pipeline therapies in various stages of development include Cadisegliatin, LY-3209590, THDB0206, CPL207280, XW014, KN056, and others.
Diabetes Pipeline Analysis
The report provides insights into:
*
The report provides detailed insights into the key companies that are developing therapies in the Diabetes Market.
*
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diabetes treatment.
*
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Diabetes market.
Download our free sample page report on Diabetes pipeline insights [https://www.delveinsight.com/sample-request/diabetes-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Diabetes Emerging Drugs
*
Cadisegliatin: vTv Therapeutics
*
LY-3209590: Eli Lilly and Company
*
THDB0206: Tonghua Dongbao Pharmaceutical
*
CPL207280: Celon Pharma
*
XW014: Sciwind Biosciences
*
KN056: Suzhou Alphamab Co., Ltd.
Diabetes Companies
More than 200 prominent companies are actively involved in developing diabetes treatments. Among these, vTv Therapeutics, Eli Lilly and Company, and Tonghua Dongbao Pharmaceutical have drug candidates that have progressed to the most advanced stage-Phase III clinical trials.
DelveInsight's report covers around 200+ products under different phases of clinical development like
*
Late stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I) along with the details of
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
Diabetes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
Diabetes Products have been categorized under various Molecule types such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Diabetes Therapies and Key Companies: Diabetes Clinical Trials and advancements [https://www.delveinsight.com/report-store/diabetes-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Diabetes Pipeline Therapeutic Assessment
- Diabetes Assessment by Product Type
- Diabetes By Stage
- Diabetes Assessment by Route of Administration
- Diabetes Assessment by Molecule Type
Download Diabetes Sample report to know in detail about the Diabetes treatment market @ Diabetes Therapeutic Assessment [https://www.delveinsight.com/sample-request/diabetes-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Content
1. Report Introduction
2. Executive Summary
3. Diabetes Current Treatment Patterns
4. Diabetes - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Diabetes Late-Stage Products (Phase-III)
7. Diabetes Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Diabetes Discontinued Products
13. Diabetes Product Profiles
14. Diabetes Key Companies
15. Diabetes Key Products
16. Dormant and Discontinued Products
17. Diabetes Unmet Needs
18. Diabetes Future Perspectives
19. Diabetes Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights Diabetes Pipeline Reports Offerings [https://www.delveinsight.com/report-store/diabetes-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=diabetes-clinical-trials-companies-therapeutic-assessment-therapies-treatment-algorithm-and-pipeline-analysis-vtv-therapeutics-tonghua-dongbao-pharmaceutical-eli-lilly-and-company-celon-phar]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Diabetes Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, and Pipeline Analysis | vTv Therapeutics, Tonghua Dongbao Pharmaceutical, Eli Lilly and Company, Celon Phar here
News-ID: 4100153 • Views: …
More Releases from ABNewswire
Utah Jewelry Company Introduces Custom-Cut Lab Diamonds | Maddie Grace Jewelry
Provo-based Maddie Grace Jewelry expands services to include custom-cut champagne lab diamonds and vintage-inspired stones. Founded in Feb 2024, the company specializes in made-to-order engagement rings and wedding bands. The expansion taps into growing demand for personalized, sustainable jewelry as lab diamonds are projected to reach 20% of global diamond sales by 2025.
PROVO, Utah - Maddie Grace Jewelry announced Tuesday that it has expanded its services to include custom-cut champagne…
Prostate Cancer Competitive Landscape 2025: Clinical Trial Analysis, Therapies, …
Prostate cancer companies are Curium, Merck, Telix Pharmaceuticals, Exelixis, AstraZeneca, AB Science, Lantheus, Pfizer, Jiangsu Hengrui Pharmaceuticals, Modra Pharmaceuticals, Bristol-Myers Squibb, MacroGenics, Syntrix Pharmaceuticals, Zenith Epigenetics, Xencor, Bristol Myers Squibb, Merus, Phosplatin Therapeutics, Laekna Therapeutics, Tavanta Therapeutics, Madison Vaccines, Taiho Pharmaceutical, Kangpu Biopharmaceuticals, Arvinas, Candel Therapeutics, Blue Earth Therapeutics, Ipsen etc
Prostate Cancer Pipeline Summary
The prostate cancer treatment landscape is rapidly advancing, with more than 150 companies developing innovative therapies across…
Pass Down App Launches Fall 2025 - Empowering Communities to Give What They Can …
Image: https://www.abnewswire.com/upload/2025/11/9505fd908f8257f7dc86a805fed73b7b.jpg
Memphis, TN - vondu Enterprises proudly announces the launch of Pass Down, a new community-driven donation marketplace designed to make giving back simple, local, and rewarding.
With the Pass Down app, individuals and businesses can post items they wish to donate-like clothing, furniture, food, or equipment-and connect directly with people in their community who need them most. Unlike traditional resale platforms, everything on Pass Down is free to give and…
Next Wave of Custom Manufacturing: Xlaserlab Brings Professional Laser Tools to …
Image: https://www.abnewswire.com/upload/2025/11/0917daa96d6afe95ad66e527389f8193.jpg
Inspired by respect for light and driven by an unwavering commitment to make lasers more accessible, Xlaserlab today changes the game in how creators, makers & and small businesses approach on-demand manufacturing with the introduction of pro-quality home workshop-focused laser tools. With the increasing need for personalized and on-demand production, Xlaserlab makes high-end laser crafting available to everyone on a portable device. For home-based creators looking to explore new…
More Releases for Diabetes
Major Force in the Diabetes Pen Market 2025: Diabetes Fuels Surge In Demand For …
How Will the Diabetes Pen Market Grow, and What Is the Projected Market Size?
The diabetes pen market is projected to grow from $29.24 billion in 2024 to $31.22 billion in 2025, at a CAGR of 6.8%. Growth is fueled by the rising need for managing diabetes, advancements in diabetes care, and an increasing focus on patient-friendly medication administration tools.
The diabetes pen market is projected to grow strongly, reaching $40.17 billion…
Diabetes Monitoring Devices Market: Regaining Its Glory| Ascensia Diabetes Care, …
The Latest Study Published by HTF MI Research on the "Diabetes Monitoring Devices Market'' evaluates market size, trend and forecast to 2029. The Diabetes Monitoring Devices market study includes significant research data and evidences to be a practical resource document for managers and analysts is, industry experts and other key people to have an easily accessible and self-analysed study to help understand market trends, growth drivers, opportunities and upcoming challenges…
Prevalence of Diabetes Drives Opportunities for Type-2 Diabetes Market
The Type-2 Diabetes Market Analysis, 2023, by MarkNtel Advisors, presents a well-researched, detail-driven, and accurate study for the stakeholders. This analysis entails prominent aspects like trends, & recent developments, drivers, opportunities, challenges, & restraints, among other parameters, influencing the overall industry expansion across different locations. This report comprises data from historic years (2018-21) & the base year (2022) to put together an estimation of the forecast period (2023-28).
According to Type-2 Diabetes Market…
Reverse Diabetes with Dr. Merritt’s Diabetes Reversal Recipe
[November 26, 2020] – People suffering from diabetes always search for ways to lower blood sugar levels in their bodies. Diabetes treatment available costs you hundreds of dollars yearly and also restricts you to a diabetic diet. That hampers your mental health and well-being. Apart from this, eye problems, kidney failure, amputations are some of the physical problems diabetic patients face.
Dr. Marlene Merritt (from the Merritt Wellness Center in…
Diabetes Treatment
Diabetes Treatment is a important way to help manage the healthy ,easy to use and improve the way of the treatment of blood glucose monitoring system.
As living standards improve, an increasing obesity, the Diabetes Treatment has improved peoples living habits, disease control effect, is becoming more and more important.
The global Diabetes Treatment market is valued at 43700 million US$ in 2018 and will reach 58000 million US$ by the end…
Self-Monitoring Blood Glucose Devices Market Study by Advance Application [Type …
The global self-monitoring blood glucose devices market was valued at $7,768 million in 2017 and is projected to reach $10,828 million by 2025 at a CAGR of 4.2% from 2018 to 2025. Monitoring of blood glucose is an essential step in diabetes management. Blood glucose monitoring devices are predominantly used to monitor a patient’s blood glucose level. Self-monitoring blood glucose (SMBG) devices are easy-to-use and enable people to monitor their…
